---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-039959"
form_type: "8-K/A"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:38:45.620465+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Absci Q2 2025 net loss $30.6M; raises $64M in July; Almirall collaboration expands

## Summary
- Q2 2025 revenue $0.6M (down from $1.3M YoY); net loss $30.6M vs $24.8M prior year.
- Cash, equivalents, and ST investments $117.5M at June 30; raised ~$64M in July, extending runway into H1 2028.
- Expanded Almirall AI drug discovery collaboration: second target elected, potential up to $650M in milestones across two programs.
- ABS-101 (anti-TL1A) Phase 1 interim readout expected H2 2025; ABS-201 (anti-PRLR) Phase 1/2a start early 2026.
- AMD strategic collaboration ongoing with $20M equity investment in Jan 2025; platform scaling using AMD Instinct accelerators.

## SEC filing metadata
- accession: 0001628280-25-039959
- form_type: 8-K/A
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01, 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828025039959/0001628280-25-039959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828025039959/absc-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-039959
- JSON: https://secwatch.observer/filing/0001628280-25-039959.json
- Plain text: https://secwatch.observer/filing/0001628280-25-039959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.